A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON)
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor: Allergan
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Allergan
Other Geographic Atrophy trials with similar outcome
This PHASE2 trial investigates Geographic Atrophy and Macular Degeneration and is currently terminated or withdrawn. Allergan leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Sep 2018 — May 2019 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .